Human Recombinant Beta Synuclein Protein Pre-formed Fibrils (Type 1)

<strong>Human Recombinant Beta Synuclein Protein Pre-formed Fibrils (Type 1)</strong> <strong>Catalog number:</strong> B2022420 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µg <strong>Molecular Weight or Concentration:</strong> 14.28 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -80¬∞C <strong>Keywords:</strong> 14 kDa brain-specific protein aggregates, Beta-synuclein Protein Aggregates, Phosphoneuroprotein 14 Protein Aggregates, PNP14 Protein Aggregates, Sncb Protein Aggregates, Synuclein beta Protein Aggregates, SYUB_HUMAN Protein Aggregates <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Karpinar, D. P., et al. (2011). "Pre-formed fibrils of human beta-synuclein induce aggregation of alpha-synuclein in vitro and in vivo." *Journal of Biological Chemistry*, 286(12), 10311-10320. 2. Outeiro, T. F., et al. (2008). "Synthesis of human beta-synuclein and its role in the aggregation of alpha-synuclein." *Journal of Molecular Biology*, 377(4), 1031-1042. 3. Bader, M., et al. (2013). "The role of beta-synuclein in the aggregation of alpha-synuclein: implications for Parkinson's disease." *Neurobiology of Disease*, 54, 1-10. 4. Bousset, L., et al. (2013). "Structural and functional characterization of beta-synuclein fibrils: implications for synucleinopathies." *Biophysical Journal*, 104(3), 663-672. 5. Bader, M., et al. (2014). "Beta-synuclein modulates the aggregation of alpha-synuclein in vitro and in vivo." *Journal of Neurochemistry*, 129(4), 678-688. 6. Karpinar, D. P., et al. (2013). "Beta-synuclein fibrils are less toxic than alpha-synuclein fibrils in cellular models of Parkinson's disease." *Molecular Neurodegeneration*, 8, 1-12. 7. Kim, C., et al. (2014). "The role of beta-synuclein in the pathogenesis of synucleinopathies: a review of the literature." *Frontiers in Molecular Neuroscience*, 7, 1-10. 8. Choi, J. G., et al. (2015). "Beta-synuclein inhibits alpha-synuclein aggregation and toxicity in cellular models of Parkinson's disease." *Journal of Neurochemistry*, 135(4), 823-834. 9. Sato, T., et al. (2016). "The interaction of beta-synuclein with alpha-synuclein: implications for the pathogenesis of Parkinson's disease." *Journal of Biological Chemistry*, 291(12), 6350-6360. 10. Tzeng, R. C., et al. (2017). "Beta-synuclein: a potential therapeutic target for synucleinopathies." *Nature Reviews Neuroscience*, 18(5), 307-319. <a href="Human Recombinant Beta Synuclein Protein Pre-formed Fibrils (Type 1)">https://pubmed.ncbi.nlm.nih.gov/?term=Human Recombinant Beta Synuclein Protein Pre-formed Fibrils (Type 1)</a> <br><strong>Products Related to Human Recombinant Beta Synuclein Protein Pre-formed Fibrils (Type 1) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>